AstraZeneca (AZN) Receives EC Marketing Approval for Brilique as Extended Treatment for Patients with History of Heat Attack
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
